Dynavax Technologies (DVAX) Peer Comparison

$15.50

$0.00 (0.00%)

As on 10-Feb-2026 16:00EDT

Market cap

$1,820 Mln

Revenue (TTM)

$331 Mln

P/E Ratio

--

P/B Ratio

3.3

Div. Yield

0 %

Edit

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Market cap ($ Mln)	1,820	3,703	36
Revenue ($ Mln)	331	587	15
Net Profit ($ Mln)	-43.40	-106.43	-62.63
Net Margin (%)	-13.13	-18.14	-410.13
RoE (%)	-8.15	--	-101.10
Price to Earnings	--	--	--
Price-To-Book	3.30	5.29	0.71

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Operating Revenue	330.51	254.93	15.27
Cost of Revenue	55.62	6.53	1.40
Gross Profit	227.80	248.40	19.89
Operating Expenses	264.46	206.18	98.45
Operating Profit (EBIT)	10.44	48.75	-84.58
Other Income	0.00	--	0.00
Profit before Tax	-40.61	53.94	-62.63
Provision for Tax	2.79	--	0.00
Profit after Tax (Net Income)	-43.40	48.83	-62.63
Minority Interest	0.00	--	0.00
Consolidated Profit	0.00	--	0.00

Liabilities ($ Mln)

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Shareholder's Funds	534.14	-107.15	50.56
Minority Interest	0.00	--	0.00
Non-Current Liabilities	305.53	435.43	50.30
Current Liabilities	106.84	67.60	21.04
Total Liabilities	986.26	395.88	231.20

Assets ($ Mln)

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Non-Current Assets	132.18	221.08	28.43
Current Assets	814.33	174.81	93.46
Total Assets	986.26	395.88	231.20
Total Debt*	285.02	--	26.10
Net Current Assets	707.49	107.21	72.42

Cashflow ($ Mln)

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Cash From Operating Activities	66.51	-10.91	-88.56
Cash Flow from Investing Activities	-18.04	--	94.53
Cash from Financing Activities	-102.02	21.86	0.25
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
ROCE (%)	3.16	-36.67	-54.77
ROE (%)	-8.15	-36.67	-101.10
ROA (%)	-3.97	14.46	-29.69
EBIT Margin (%)	-10.25	--	-414.88
Net Margin (%)	-13.13	19.16	-410.13
Cash Profit Margin (%)	0.00	--	0.00

Growth Ratios

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Revenue Growth (%)	26.73	0.60	-17.82
EBIT Growth (%)	-207.38	--	35.12
Net Profit Growth (%)	-311.94	2,791.18	56.95
EPS Growth (%)	-420.34	--	45.40
Book Value Growth (%)	-11.08	--	-52.03

Valuation Ratios

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Price / Earnings	71.55	--	-0.05
Price / Book Value	3.27	--	0.08
Dividend Yield (%)	--	--	--
EV/EBITDA	32.71	--	1.14
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Debt to Equity	0.41	--	0.00
Short term debt to equity ratio	0.08	--	0.13
Current Ratio	7.62	2.59	4.44
Quick Ratio	6.94	--	4.44
Interest Coverage	-5.33	--	--

Operating Efficiency Ratios

	Dynavax Technologies (DVAX)	aTyr Pharma (LIFE)	Generation BioÂ Co (GBIO)
Debtors to sales (%)	22.18	17.80	2.56
Asset Turnover	0.30	0.75	0.07
Receivable days	60.23	45.21	52.39
Inventory Days	455.57	-182.56	282.66
Payable days	52.84	1,307.87	139.03
Cash Conversion Cycle	462.96	-649.00	196.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly